-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 27th, the “China Enterprise News” group, the special issue department of Consumer Daily, the column group of “Discover Brands”, the online version of the People’s Daily Market News Brand Power · Independent Brand Selection Demonstration Project, University of International Business and Economics China International Brand Strategy The 2021 (eighth) Chinese brand influence evaluation results release event jointly sponsored by the Research Center and other units was held in Beijing.
With the theme of "Developing the Brand Economy and Promoting the Optimization and Upgrade of the Economic System", this event invites leaders and experts in different fields to focus on quality improvement actions, brand innovation and development, and foster new technologies, new products, new formats, and new models.
Collateral disease theoretical innovation research is a model of traditional Chinese medicine inheritance and innovation in recent years.
In recent years, the development of Yiling Pharmaceutical has entered the fast lane, ranking among the top 500 listed companies in China by market value, the top 500 most valuable brands in China, the Top 10 Chinese medicine companies, and the top 20 listed Chinese pharmaceutical companies.
The company developed Tongxinluo Capsules, Shensong Yangxin Capsules, Qiliqiangxin Capsules, Lianhua Qingwen Capsules (granules), Lianhua Qingke Tablets, Yangzheng Xiaoji Capsules, Jinlida Granules, Bazi Bushen Innovative patented Chinese medicines such as capsules have carried out evidence-based medical research, and have been included in the disease diagnosis and treatment guidelines and expert consensus issued by the Chinese Medical Association and the Chinese Association of Integrative Medicine.
Among them, the subsidiary Hebei Yiling Medical Research Institute as the first main research unit completed the "Traditional Chinese Medicine Vein Theory Construction and Its Guidance for the Prevention and Treatment of Microvascular Diseases" project involving the three major products of Tongxinluo, Shensongyangxin and Qiliqiangxin.
In addition, Yiling Pharmaceutical's respiratory system products have become Chinese patent medicines for colds.
At present, the company's many Chinese medicine varieties have been registered and sold in South Korea, Vietnam, Russia, Canada, Singapore, Indonesia and other countries.
On May 27th, the “China Enterprise News” group, the special issue department of Consumer Daily, the column group of “Discover Brands”, the online version of the People’s Daily Market News Brand Power · Independent Brand Selection Demonstration Project, University of International Business and Economics China International Brand Strategy The 2021 (eighth) Chinese brand influence evaluation results release event jointly sponsored by the Research Center and other units was held in Beijing.
With the theme of "Developing the Brand Economy and Promoting the Optimization and Upgrade of the Economic System", this event invites leaders and experts in different fields to focus on quality improvement actions, brand innovation and development, and foster new technologies, new products, new formats, and new models.
Collateral disease theoretical innovation research is a model of traditional Chinese medicine inheritance and innovation in recent years.
In recent years, the development of Yiling Pharmaceutical has entered the fast lane, ranking among the top 500 listed companies in China by market value, the top 500 most valuable brands in China, the Top 10 Chinese medicine companies, and the top 20 listed Chinese pharmaceutical companies.
The company developed Tongxinluo Capsules, Shensong Yangxin Capsules, Qiliqiangxin Capsules, Lianhua Qingwen Capsules (granules), Lianhua Qingke Tablets, Yangzheng Xiaoji Capsules, Jinlida Granules, Bazi Bushen Innovative patented Chinese medicines such as capsules have carried out evidence-based medical research, and have been included in the disease diagnosis and treatment guidelines and expert consensus issued by the Chinese Medical Association and the Chinese Association of Integrative Medicine.
Among them, the subsidiary Hebei Yiling Medical Research Institute as the first main research unit completed the "Traditional Chinese Medicine Vein Theory Construction and Its Guidance for the Prevention and Treatment of Microvascular Diseases" project involving the three major products of Tongxinluo, Shensongyangxin and Qiliqiangxin.
In addition, Yiling Pharmaceutical's respiratory system products have become Chinese patent medicines for colds.
At present, the company's many Chinese medicine varieties have been registered and sold in South Korea, Vietnam, Russia, Canada, Singapore, Indonesia and other countries.
